Q1 2020 Corcept Therapeutics Inc Earnings Call Transcript
(technical difficulty)
our commercial business for the rest of the year. The risks COVID-19 poses to patients with Cushing's syndrome are likely to increase demand for Korlym. At the same time, restrictions imposed by state and local governments, hospitals and individual medical practices make it very difficult to work with physicians in-person. Some of the imaging centers and laboratories positioned to use when diagnosing patients with Cushing's syndrome and titrating to an optimum dose of Korlym are closed.
Many patients are hesitant to leave their homes even to visit the doctor. These factors are likely to reduce the rate at which new patients are introduced to Korlym and make it more difficult for physicians to monitor patients following dose titration. However, as physicians and patients adapt to a world in which COVID-19 is endemic, as they are beginning to do, the impact of these factors may diminish. We will reaffirm our 2020 revenue guidance of $355 million to $375 million based on our strong first quarter results and our best estimate of how the factors that determine our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |